Six Courses of Intensified CHOP Plus G-CSF Compared to Eight Courses of Standard CHOP in Patients with Intermediate-Risk Aggressive Non-Hodgkin Lymphoma …
LF Verdonck, GW van Imhoff, JMM Raemakers… - 2005 - ashpublications.org
Abstract Between November 1994 and February 2004 a total of 513 untreated patients with
aggressive intermediate-risk NHL, aged 16–65 years, were recruited to the randomized …
aggressive intermediate-risk NHL, aged 16–65 years, were recruited to the randomized …
Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin …
LF Verdonck, A Notenboom, DD de Jong… - Blood, 2007 - ashpublications.org
Optimal dose and timing of CHOP (cyclophosphamide, doxorubicin, vincristine, and
prednisone) chemotherapy for aggressive non-Hodgkin lymphoma (NHL) is still an …
prednisone) chemotherapy for aggressive non-Hodgkin lymphoma (NHL) is still an …
High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
MA Shipp, D Neuberg, M Janicek… - Journal of clinical …, 1995 - ascopubs.org
PURPOSE To purpose of this study was to develop a more effective approach to the
treatment of patients with poor-prognosis aggressive non-Hodgkin's lymphoma (NHL) …
treatment of patients with poor-prognosis aggressive non-Hodgkin's lymphoma (NHL) …
Dose-intensified CHOP (double-CHOP) followed by consolidation with high-dose chemotherapy for high and high-intermediate risk aggressive non-Hodgkin's …
T Yamazaki, U Sawada, Y Kura, T Ito… - Leukemia & …, 2002 - Taylor & Francis
Patients with aggressive non-Hodgkin's lymphoma (NHL) showing several risk factors have
a poor prognosis. In such patients, conventional chemotherapy results in a low complete …
a poor prognosis. In such patients, conventional chemotherapy results in a low complete …
[PDF][PDF] A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non …
M van Agthoven, P Sonneveld, A Hagenbeek… - The Hematology …, 2003 - repub.eur.nl
It has frequently been questioned whether results of trials can be generalized to routine
clinical practice. Results obtained with standard cyclophosphamide, doxorubicin, vincristine …
clinical practice. Results obtained with standard cyclophosphamide, doxorubicin, vincristine …
Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma
K Itoh, T Ohtsu, H Wakita, T Igarashi, K Ishizawa… - Annals of oncology, 2000 - Elsevier
Background CHOP is accepted as the gold standard for first line chemotherapy of
aggressive non-Hodgkin's lymphoma (NHL). A dose-escalation study of CHOP was …
aggressive non-Hodgkin's lymphoma (NHL). A dose-escalation study of CHOP was …
Successful application of a previously derived prognostic index in the analysis of a randomised trial of 281 patients with high grade non-Hodgkin's lymphoma …
RCF Leonard, RJ Prescott, JH Mao, JM White - Annals of oncology, 1993 - Elsevier
Background The selection of patients for experimental therapies for high grade non-
Hodgkin's lymphoma (NHL) is now recognised to be very influential in affecting results. We …
Hodgkin's lymphoma (NHL) is now recognised to be very influential in affecting results. We …
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87–2 protocol—a groupe d'Etude des …
C Haioun, E Lepage, C Gisselbrecht… - Journal of Clinical …, 2000 - ascopubs.org
PURPOSE: To present the final analysis, with a median follow-up of 8 years, of the LNH87–2
randomized study, which compares consolidative sequential chemotherapy (ifosfamide plus …
randomized study, which compares consolidative sequential chemotherapy (ifosfamide plus …
[HTML][HTML] Dose-escalation of CHOP in non-Hodgkin's lymphoma
A Santoro, M Balzarotti, C Tondini, M Zanini… - Annals of oncology, 1999 - Elsevier
Background CHOP is considered to be the gold standard for patients with histologically
aggressive non-Hodgkin's lymphoma both in limited and advanced stages. In order to …
aggressive non-Hodgkin's lymphoma both in limited and advanced stages. In order to …
Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a …
R Bouabdallah, D Coso, R Costello… - Bone marrow …, 2000 - nature.com
It is now established that a subgroup of non-Hodgkin's lymphoma (NHL) patients probably
benefit from high-dose therapy (HDT). We therefore retrospectively analyzed survival of 126 …
benefit from high-dose therapy (HDT). We therefore retrospectively analyzed survival of 126 …